Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Freeline

28.09.2020

Freeline announces promotion of Romuald Corbau, Ph.D. to Chief Scientific Officer (3)

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces that Romuald Corbau, Ph.D. has been promoted to the role of Chief Scientific Officer. The Founder of Freeline, Professor Amit Nathwani, will continue in his role as Clinical and Scientific Adviser and member of the Board of Directors of the Company.
Freeline

23.09.2020

Freeline announces supply agreement for haemophilia B program

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. (“Thermo Fisher”).
Freeline

10.09.2020

Freeline to participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that Theresa Heggie, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15 at 8.00 am EDT.
Freeline

20.07.2020

Freeline files registration statement for proposed initial public offering in the United States

Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.
Freeline

13.07.2020

Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting

Freeline, a clinical stage, Adeno-Associated Virus (AAV) based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced new data on its AAV gene therapy product candidate, FLT180a, in severe Haemophilia B patients at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress. The data presented in an oral presentation by Professor Pratima Chowdary of the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital UK and UCL Cancer Institute, and Principal Investigator for the study, demonstrated with data up to two years for the earliest cohort, that a dose of between 7.5e11 and 9.75e11 vg/kg has the potential to create durable Factor IX (FIX) activity levels in the normal range in patients with severe Haemophilia B.
Freeline

30.06.2020

Freeline Closes $120 Million Series C Financing Round

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million extended Series C financing. The financing augments Syncona’s previously announced Series C investment in Freeline of $40 million (£30.6 million) with an additional $80 million (£61.2 million) of new capital. The round was led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.
Freeline

30.06.2020

Freeline Announces Additional Financing Plans

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States. The timing and the terms of any such additional capital raising have not yet been determined and are subject to market conditions and other factors. There is no assurance that any such additional capital raising will be completed.
Freeline

29.06.2020

Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that Professor Pratima Chowdary of the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital UK and UCL Cancer Institute, and Chief investigator for the study, will present data in a late-breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on behalf of co-authors, which will be held virtually 12-14 July 2020. In addition, Freeline has five posters at the conference and will be presenting data on the Factor IX Padua variant and health economics from its Adeno-Associated Virus (AAV)-based haemophilia gene therapy platform.
Freeline

14.05.2020

Gene Therapy Explained

An animation explaining what gene therapy is, how it has evolved over 50 years and the goal of providing a long-term cure for patients who receive treatment.
Freeline

04.05.2020

Freeline receives Orphan Drug Designation from the FDA for FLT190 for the treatment of Fabry Disease

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for FLT190 for the treatment of Fabry Disease. This comes soon after Freeline announced it had received Orphan Drug Designation for FLT190 from the European Commission, based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency.

Load More